On Oct. 16, 2017, Ablynx, a Belgian biopharmaceutical company focused on the discovery and development of nanobodies, announced the establishment of its US-based subsidiary, Ablynx, Inc., and the appointment of Daniel Schneider as general manager to lead the commercialization of caplacizumab inOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.